




MEDICINAL PRODUCTS 2023

IMMUCELL CORP DE
Rank 19 of 48

ImmuCell





MEDICINAL PRODUCTS 2023

IMMUCELL CORP DE
Rank 19 of 48

ImmuCell

The relative strengths and weaknesses of IMMUCELL CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMMUCELL CORP DE compared to the market average is the variable Property, Plant and Equipment, Net, increasing the Economic Capital Ratio by 54% points. The greatest weakness of IMMUCELL CORP DE is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 29% points.

The company's Economic Capital Ratio, given in the ranking table, is 79%, being 84% points above the market average of -5.0%.

Input Variable	Value in 1000 USD
Assets, Current	13,995
Assets, Non-Current	2,271
General and Administrative Expense	16,373
Goodwill	153
Liabilities, Current	3,072
Liabilities, Non-Current	11,409
Other Assets	0
Other Compr. Net Income	0
Other Expenses	7.7
Other Liabilities	0
Other Net Income	-187
Other Revenues	18,568
Property, Plant and Equipment, Net	28,442
Research and Development	4,494

Output Variable	Value in 1000 USD
Liabilities	14,481
Assets	44,861
Expenses	20,875
Revenues	18,568
Stockholders Equity	30,380
Net Income	-2,494
Comprehensive Net Income	-2,494
Economic Capital Ratio	79%